Fig. 7: Proposed mechanism of increased RSV B neutralization potency with nirsevimab binding site substitution Q209R.

Red indicates the electrostatics of the negatively charged pocket on nirsevimab, created by glutamic and aspartic acids (E55 and D101). Green dashed lines indicate polar contacts. F fusion protein, RSV respiratory syncytial virus.